Iovance Biotherapeutics, Inc.
NEWS
Shares of Iovance Biotherapeutics shot up Tuesday on rumors the company could be up for sale.
Lytix Biopharma AS announces a clinical collaboration with the US-based company Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte technology, to evaluate Lytix`s first-in-class oncolytic peptide, LTX-315, in combination with Iovance`s autologous ready to infuse T cell therapy.
There has been a spate of recent news regarding the expansion of facilities and the expected job growth for the biopharma and life sciences industry. Here’s a look at some of those stories.
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
In an exclusive interview with BioSpace, Iovance CEO Maria Fardis said the company’s goal is to add headcount to support its growth strategy. The company currently has about 100 full-time employees.
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
Maria Fardis, chief executive officer of Iovance Biotherapeutics, sees tumor infiltrating lymphocyte (TIL) therapies as the best immunotherapy option to treat solid cancers.
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
JOBS
IN THE PRESS